Review decision – December 2018

Decision to move the existing guidance to the static list

We would like to update you on the decision made regarding the review of the existing guidance on TA370; Bortezomib for previously untreated mantle cell lymphoma.

No new evidence was identified that is likely to change the existing recommendations in TA370. 

NICE’s Guidance Executive has decided to proceed with this proposal without consultation.

Consequently, TA370 will move to the ‘static list’ of technology appraisals.

Review decision paper

Matrix of stakeholders

This page was last updated: